{
Jo Walton

People

}
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-312025-03-311111100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-312025-03-311111100
Download SVG
Download PNG
Download CSV

ubs maintains neutral rating for novo nordisk with target price of 1100 kroner

UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted that the market is likely to respond positively to the figures, particularly due to a significant cap on the sales target.
MarketScreener
Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
09:40 06.11.2024

ubs maintains neutral rating for novo nordisk with target price of 1100 kroner

UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted a moderate increase in prescription figures for the weight loss drug Wegovy in the USA, based on the latest data.
MarketScreener
United States Dollar Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
13:26 04.11.2024

ubs maintains neutral rating for gsk with target price of 1580 pence

UBS has maintained a 'Neutral' rating for GSK, setting a target price of 1580 pence. Analyst Jo Walton has slightly increased his 2025 estimates but expresses skepticism about the outlook for the Shingrix vaccine in China starting in 2026.
MarketScreener
British Pound Sterling UBS AG GSK plc GBR Jo Walton
TradFi, Market Report
12:42 31.10.2024

ubs maintains neutral rating on gsk with target price of 1580 pence

UBS has maintained a 'Neutral' rating on GSK, setting a target price of 1580 pence. Analyst Jo Walton noted that a discussion with the CFO indicated potential for further margin improvement following the release of quarterly figures. As of October 30, GSK's stock was trading at €16.945, reflecting a 3.75% decline.
aktiencheck.de
British Pound Sterling Glaxo Smith Kline plc GBR Jo Walton
TradFi, Market Report
12:52 30.10.2024

ubs maintains neutral rating for novo nordisk with target price of 1100 kroner

UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted a gradual increase in prescriptions for the weight-loss drug Wegovy in the US, reflecting positive trends in its market performance.
ch.marketscreener.com
Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
15:02 28.10.2024

ubs maintains neutral rating for novo nordisk with target price of 1100 kroner

UBS has maintained a 'Neutral' rating for Novo Nordisk, setting a target price of 1100 Danish crowns. Analyst Jo Walton noted a gradual increase in prescriptions for the weight loss drug Wegovy in the US, reflecting positive trends in its market performance.
MarketScreener
Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
15:02 28.10.2024

ubs maintains neutral rating for novo nordisk with target price of 1100 kroner

UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1100 Danish kroner. Analyst Jo Walton noted a gradual increase in prescriptions for the weight-loss drug Wegovy in the US, reflecting positive trends in its market performance.
boerse.de
Danish Krone Novo Nordisk A/S DNK Jo Walton
TradFi, Market Report
14:15 28.10.2024

ubs maintains buy rating for sanofi with target price of 110 euros

UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros. Analyst Jo Walton highlighted the company's strong growth distribution in his review of the quarterly report, indicating potential for revaluation.
MarketScreener
Euro Sanofi FRA Jo Walton
TradFi, Market Report
09:50 28.10.2024

ubs maintains buy rating for sanofi with target price of 110 euros

UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros following the company's third-quarter results. Analyst Jo Walton noted that sales surpassed both his and consensus estimates, largely driven by strong vaccine sales.
MarketScreener
Euro Sanofi FRA CHE Jo Walton
TradFi, Market Report
13:25 25.10.2024

UBS maintains buy rating for Sanofi with target price of 110 euros

UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros following the company's strong third-quarter results. Analyst Jo Walton noted that sales surpassed both his and consensus estimates, largely driven by vaccine sales.
boerse.de
Euro Sanofi FRA CHE Thomas Müller Hubert Dichtl Jo Walton Warren Buffet Show more
TradFi, Market Report
12:37 25.10.2024
Trending
Subcategory
Stock Market Updates Corporate News Industry Trends Global Trade Developments Global Financial Events Banking Regulations Retail and Consumer Goods Startups & Entrepreneurship Central Bank Actions Finance Mergers & Acquisitions Industry Mergers & Acquisitions Inflation and Monetary Impact Government Economic Policies CEO Changes Market Analysis and Predictions Domestic Politics Government Policies Workplace Trends GDP Growth & Recession Forecasts Financial Scams and Security
Countries:
USA CHN GBR CHE IND DEU JPN FRA CAN VNM ARE ESP MEX ITA SGP AUS TWN THA MYS IDN
Companies:
Tesla, Inc. Apple Inc. Barclays PLC JPMorgan Chase & Co. Deutsche Bank Money Market PP The Goldman Sachs Group, Inc. Credit Suisse Strategic Income I Banco Santander, S.A. Berkshire Hathaway Inc. SpaceXCoin USD Bank of America Corporation Morgan Stanley BNP Paribas SA Amazon.com, Inc. UBS Group AG Lloyds Banking Group plc NVIDIA Corporation Bank Frick AG Citigroup Inc. Wells Fargo & Company
Currencies:
United States Dollar Euro British Pound Sterling Japanese Yen Swiss Franc Indian Rupee Chinese Yuan South Korean Won Vietnamese Đồng Canadian Dollar Australian Dollar Thai Baht Indonesian Rupiah Singapore Dollar Mexican Peso New Taiwan Dollar Russian Ruble Hong Kong Dollar Offshore Chinese Yuan New Zealand Dollar
People:
Donald Trump Elon Musk JD Vance Warren Buffett Sergio Ermotti Mark Haefele Jennifer Piepszak Karoline Leavitt Ursula von der Leyen Olivier Calvet Scott Bessent George Saravelos Francois Xavier Bouvignies Joseph Spak Robin Leopold Stefan Rauti Susan P. Crawford Greg Rubini Dan Ives Savio D'souza

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.